Lexeo Therapeutics, Inc. Common Stock LXEO
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-14T01:13:20.329Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T22:36:28.290946041Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-14T01:13:19.642789+00:00
Lexeo Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.09 | 534.7% | 42.0% | |||
| 25Δ | 2.44 | 539.9% | 38.7% | |||
| 30Δ | 2.80 | 545.1% | 35.3% | |||
| 35Δ | 3.15 | 550.3% | 32.0% | |||
| 40Δ | 3.51 | 555.6% | 28.7% | |||
| 45Δ | 3.86 | 560.8% | 25.4% | |||
| 50Δ | 4.21 | 566.0% | 22.1% | |||
| 55Δ | 4.57 | 571.3% | 18.7% | |||
| 60Δ | 4.92 | 576.5% | 15.4% | |||
| 65Δ | 5.92 | 598.2% | 13.1% | |||
| 70Δ | 7.10 | 624.6% | 11.1% | |||
| 75Δ | 8.28 | 651.0% | 9.1% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.09
- IV
- 534.7%
- B/E move
- 42.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.44
- IV
- 539.9%
- B/E move
- 38.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.80
- IV
- 545.1%
- B/E move
- 35.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.15
- IV
- 550.3%
- B/E move
- 32.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.51
- IV
- 555.6%
- B/E move
- 28.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.86
- IV
- 560.8%
- B/E move
- 25.4%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.21
- IV
- 566.0%
- B/E move
- 22.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.57
- IV
- 571.3%
- B/E move
- 18.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.92
- IV
- 576.5%
- B/E move
- 15.4%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.92
- IV
- 598.2%
- B/E move
- 13.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.10
- IV
- 624.6%
- B/E move
- 11.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.28
- IV
- 651.0%
- B/E move
- 9.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
LXRX
Description unavailable
More →LYEL
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South…
More →MANE
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New…
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and…
More →MCRB
Description unavailable
More →